Aruna Bio

[Available On-Demand]
Aruna Bio, Inc., is the leader in the development of neural exosomes for the treatment of neurodegenerative diseases. The company is utilizing its proprietary neural exosome platform and manufacturing capability to develop a pipeline of therapeutics capable of revolutionizing the treatment of a range of neurodegenerative disorders such as Parkinson’s, Multiple Sclerosis, as well as Stroke, where significant unmet medical need exists today.
Neural exosomes are capable of reaching the site of injury or disease in the brain or CNS and have the ability to treat diseases on their own based on their anti-inflammatory, self-repair and protective mechanisms of action. In addition to having the ability on their own to favorably alter the course of serious neurodegenerative diseases and stroke, exosomes are capable of carrying other therapies (“payloads”), such as antibodies, small molecules and genes across the blood brain barrier and to the site of disease or damage.
Company Type:
Company Website:
Company HQ State:
Georgia
Company HQ Country:
United States
Year Founded:
2002
Main Therapeutic Focus:
Lead Product in Development:
AB126
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
ArunA Bio